Biosyent Inc

OTC Pink - Current Information:BIOYFUnited StatesView on Canadian Exchange

Nov 20, 2024

Show headlines and story abstract

• BioSyent Releases Financial Results for Q3 and YTD 2024, from 8:00AM ET on Wednesday Nov 20, 2024 by Dow Jones

  8:00AM ET on Wednesday Nov 20, 2024 by Dow Jones
  Companies Mentioned: RX
  
  This press release may contain information or statements that are forward-looking. The contents herein represent our judgment, as at the release date, and are subject to risks and uncertainties that may cause actual results or outcomes to be materially different from the forward-looking information or statements. Potential risks may include, but are not limited to, those associated with clinical trials, product development, future revenue, operations, profitability and obtaining regulatory approvals. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.
  

• BioSyent Declares Fourth Quarter 2024 Dividend, from 7:55AM ET on Wednesday Nov 20, 2024 by Dow Jones

  7:55AM ET on Wednesday Nov 20, 2024 by Dow Jones
  Companies Mentioned: RX
  
  BioSyent Declares Fourth Quarter 2024 Dividend
  
  MISSISSAUGA, Ontario, Nov. 20, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. ("BioSyent", "the Company", TSX Venture: RX) is pleased to announce that its Board of Directors has declared a quarterly dividend of $0.045 per common share, payable in Canadian Dollars on December 16, 2024, to shareholders of record at the close of business on November 29, 2024. This fourth quarter 2024 dividend compares with the third quarter 2024 dividend of $0.045 per common share. This dividend qualifies as an 'eligible dividend' for Canadian income tax purposes. The declaration, timing, amount and payment of future dividends remain at the discretion of the Board of Directors.